technology Merger --> In a release, the company noted that the non-binding letter of intent outlines the primary terms of a merger of
Histogen's solutions are based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. The technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of proteins that have been shown to support stem cell growth and differentiation. Histogen's lead product,
"Histogen's technology platform opens a spectrum of potential product opportunities in both aesthetics and therapeutics, an ideal fit with our vision for Restorgenex," said
Following successful completion of this proposed merger, the company's goal is to build Restorgenex into a cosmeceutical and pharmaceutical company in the expanding fields of dermatology and hair restoration. The parties intend to move toward a formal merger agreement in which Histogen would become a subsidiary, Histogen founder
"I am very excited about the potential of a merger between Histogen and Restorgenex, and look forward to moving into the next stage," said Dr. Naughton. "It is an honor to be working with biotechnology visionaries Dr.
Dr. Naughton has spent more than 25 years researching the tissue engineering process, holds more than 95 U.S. and foreign patents, and has been honored for her work in the field by organizations including receiving the Intellectual Property Owners Association Inventor of the Year Award.
Prior to founding Histogen in 2007, Dr. Naughton oversaw the design and development of the world's first up-scaled manufacturing facility for tissue engineered products, was pivotal in raising over
"I believe the potential acquisition of Histogen, and the expertise and vision Dr. Naughton will bring as Chief Executive Officer will be a tremendous asset in ushering the Company into the biotechnology industry," said
((Comments on this story may be sent to firstname.lastname@example.org))
In a release, the company noted that the non-binding letter of intent outlines the primary terms of a merger of